VU0155041

• 产品号: V1640
• 分子式: C14H15Cl2NO3
• 分子量: 316.1798
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: VU0155041
• IUPAC标准名: (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
• IUPAC传统名: (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
• 别名: (±)-cis-2-(3,5-Dicholorphenylcarbamoyl)cyclohexanecarboxylic acid

产品登记号

• MDL号: MFCD03544581

产品性质

• Empirical Formula (Hill Notation): C14H15Cl2NO3
• 纯度: ≥98% (HPLC)
• 外观: white powder
• 溶解度: DMSO: soluble54 mg/mL
• GHS警示词: Warning
• GHS危险声明: H302
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• 危险公开号: 22
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
VU0155041 is a mixed allosteric agonist/positive allosteric modulator (PAM) of mGluR4. VU0155041 is approximately 8-fold more potent than PHCCC and does not show any significant potentiator or antagonist activity at other mGluR subtypes. It is soluble in an aqueous vehicle and intracerebroventricular administration of 31-316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041 exhibits selectivity for mGluR4 relative to 67 different targets and does not affect the function of striatal NMDA receptors.
VU0155041 is a positive allosteric modulator of the metabotropic glutamate receptor subtype 4. It also shows some direct agonist activity, but at a site different from the glutamate binding site. /VU0155041 is approximately 8-fold more potent than PHCCC and enhances the activity of glutamate also about 8-fold. It shows promising anti-Parkinsonian effects in animal models of Parkinson′s disease.

详细说明 (简体中文)

Biochem/physiol Actions
VU0155041 is a mixed allosteric agonist/positive allosteric modulator (PAM) of mGluR4. VU0155041 is approximately 8-fold more potent than PHCCC and does not show any significant potentiator or antagonist activity at other mGluR subtypes. It is soluble in an aqueous vehicle and intracerebroventricular administration of 31-316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041 exhibits selectivity for mGluR4 relative to 67 different targets and does not affect the function of striatal NMDA receptors.
VU0155041 is a positive allosteric modulator of the metabotropic glutamate receptor subtype 4. It also shows some direct agonist activity, but at a site different from the glutamate binding site. /VU0155041 is approximately 8-fold more potent than PHCCC and enhances the activity of glutamate also about 8-fold. It shows promising anti-Parkinsonian effects in animal models of Parkinson′s disease.